Reduction of fever and streptococcal bacteremia in granulocytopenic patients with cancer. A trial of oral penicillin V or placebo combined with pefloxacin. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer

OBJECTIVE--To determine the effect of oral penicillin V combined with a fluoroquinolone (pefloxacin) on the occurrence of fever and streptococcal and other gram-positive coccal bacteremic infections in granulocytopenic patients with cancer. DESIGN--Prospective randomized double-blinded placebo-controlled prophylactic trial. SETTING--Inpatient setting in multiple cooperating cancer centers. SUBJECTS--Convenience sample with a total of 551 granulocytopenic patients, 95% of whom had leukemia or underwent bone marrow transplantation. INTERVENTIONS--Penicillin V (500 mg twice a day) vs placebo given in combination with oral pefloxacin (400 mg twice a day). MAIN OUTCOME MEASURES--Occurrence of fever and/or infection. RESULTS--Fever or infection (without fever) developed in 190 (71%) of 268 evaluable patients in the penicillin arm compared with 213 (80%) of 268 evaluable patients in the placebo arm (P = .03; 95% confidence interval [CI] for the difference, -16% to -1%). Bacteremia occurred in 58 (22%) of 268 placebo-treated patients and in 38 (14%) of 268 penicillin-treated patients (P = .03; 95% CI for the difference, -14% to -1%), primarily due to a reduction in streptococcal bacteremic episodes that occurred in 14 penicillin-treated patients (5%) and in 27 placebo-treated patients (10%) (P = .05; 95% CI for the difference, -9% to -0.3%). Gram-negative rod bacteremias occurred in only two patients (1%) and in five patients (2%), respectively. Logistic regression analysis also supported the treatment effect on the development of bacteremia. CONCLUSIONS--These results demonstrate that the addition of penicillin V to fluoroquinolone prophylaxis in granulocytopenic patients with cancer effectively reduces febrile episodes and the incidence of bacteremia, especially that due to streptococcal species.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis
Gafter-Gvili et al.
J Antimicrob Chemother 2007;59:5-22.
ABSTRACT | FULL TEXT  

Meta-Analysis: Antibiotic Prophylaxis Reduces Mortality in Neutropenic Patients
Gafter-Gvili et al.
ANN INTERN MED 2005;142:979-995.
ABSTRACT | FULL TEXT  

Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: a systematic review and meta-analysis of randomized trials
Vidal et al.
J Antimicrob Chemother 2004;54:29-37.
ABSTRACT | FULL TEXT  

Medical Management of the Acute Radiation Syndrome: Recommendations of the Strategic National Stockpile Radiation Working Group
Waselenko et al.
ANN INTERN MED 2004;140:1037-1051.
ABSTRACT | FULL TEXT  

Reappraisal With Meta-Analysis of the Addition of Gram-Positive Prophylaxis to Fluoroquinolone in Neutropenic Patients
Cruciani et al.
JCO 2003;21:4127-4137.
ABSTRACT | FULL TEXT  

The Hematologist and Radiation Casualties
Dainiak et al.
ASH Education Book 2003;2003:473-496.
ABSTRACT | FULL TEXT  

In Vitro Activities of the New Ketolide HMR 3647 (Telithromycin) in Comparison with Those of Eight Other Antibiotics against Viridans Group Streptococci Isolated from Blood of Neutropenic Patients with Cancer
Alcaide et al.
Antimicrob. Agents Chemother. 2001;45:624-626.
ABSTRACT | FULL TEXT  

Rifampin Does Not Improve the Efficacy of Quinolone Antibacterial Prophylaxis in Neutropenic Cancer Patients: Results of a Randomized Clinical Trial
Gomez-Martin et al.
JCO 2000;18:2126-2134.
ABSTRACT | FULL TEXT  

Alpha Hemolytic Streptococcal Infection During Intensive Treatment for Acute Myeloid Leukemia: A Report From the Children's Cancer Group Study CCG-2891
Gamis et al.
JCO 2000;18:1845-1855.
ABSTRACT | FULL TEXT  

Oral Antimicrobial Prophylaxis in Bone Marrow Transplant Recipients: Randomized Trial of Ciprofloxacin versus Ciprofloxacin-Vancomycin
Ford et al.
Antimicrob. Agents Chemother. 1998;42:1402-1405.
ABSTRACT | FULL TEXT